StepStone leads a US Fertility continuation vehicle, and the price stays private

PE Hub reported on Sept. 14 that StepStone is leading a continuation vehicle backing Amulet's US Fertility, and the item carries no price at all—no vehicle size, no split between rolled and fresh capital, no account of how existing LPs were treated. The familiar structure has the same company moving into a new pool of capital under the same manager while older-fund LPs get the chance to sell at a price the sponsor sets and the lead buyer negotiates, but those terms are exactly what the item leaves unstated.

What the item does carry is the asset's self-description. US Fertility calls itself, in PE Hub's phrasing, the nation's largest partnership of physician-owned and physician-led fertility practices and IVF laboratories, and says it has helped more than 400,000 individuals and couples build families. Both are company claims rather than audited figures, and the count of families served is a demand statistic—the easy half of underwriting a fertility platform.

The harder half is supply: a business assembled from physician-owned practices grows by buying more practices, and the multiple it pays for the next one decides whether the last one was a good purchase. That is the number the item never mentions.

What a sponsor typically gets from a continuation vehicle is straightforward: the asset stays under management, the fee stream continues on a fresh clock instead of winding down with the original fund, and a rollover election from existing LPs is a verdict on the mark. That is the trade Amulet is making by handing US Fertility to a new vehicle.

Continuation vehicles, as this publication has argued, are no longer an alternative to the exit market; they are the mechanism that sets prices inside it. The argument usually runs from the LP's side, where liquidity is exchanged for a mark nobody outside the deal can independently verify. A buyer-side version binds just as hard in a roll-up, because a lead investor in a platform that acquires physician practices is pricing a pipeline, and pipelines are typically valued off the multiples the platform itself has been paying—the least externally checkable inputs in the model.

If the growth is acquisition-led, the asset is a sensible candidate for the extra hold a continuation vehicle buys and a hard one to price. A lead in a single-asset deal sits in the data room and builds its own model, while LPs who elect to roll are deciding on the sponsor's number with less. The figure that would settle the question—what the vehicle paid against Amulet's carried value for US Fertility—does not appear in the coverage.